Phase II Evaluation of VDC-1101 in Canine Cutaneous T-Cell Lymphoma

September 2014 in “ Journal of Veterinary Internal Medicine ”

Michelle A. Morges, Jenna H. Burton, Corey Saba, David M. Vail, Kristine Burgess, Douglas H. Thamm

cutaneous T-cell lymphoma CTCL VDC-1101 dermatopathies

TLDR VDC-1101 shows potential as a treatment for canine cutaneous T-cell lymphoma.

The study evaluated the efficacy of VDC-1101 in 12 dogs with cutaneous T-cell lymphoma (CTCL). The treatment involved a 30-minute IV infusion every 21 days, alongside prednisone. Among 11 evaluable dogs, the objective response rate (ORR) was 45%, with 1 complete response (CR), 4 partial responses (PR), 2 stable disease (SD), and 4 progressive disease (PD). The median progression-free survival (PFS) was 37.5 days, with one dog maintaining a CR for over a year. Adverse events were mild, with gastrointestinal and hematologic issues being the most common. The study concluded that VDC-1101 showed activity against canine CTCL and could be a potential treatment option for this disease.

View this study on onlinelibrary.wiley.com →

Discuss this study in the Community →

Related Community Posts Join

6 / 12 results

community New and Interesting HairLoss Studies/Papers/Reviews

in Treatment 44 upvotes 4 years ago

Hair loss treatments discussed include Dutasteride with Ketoconazole, tissue engineering strategies, and androgenetic alopecia therapies. Massage doubles follicular retention, improving treatment effectiveness.

community How do you use rosemary oil and peppermint oil?

in Question 6 upvotes 4 years ago

Rosemary oil and peppermint oil may promote hair growth and increase cutaneous blood flow, showing promise as treatments for androgenetic alopecia. Minoxidil 2% is also used for treating hair loss.

community Scientific evidence for Peppermint & Rosemary oils + My Experience

in Research/Science 114 upvotes 1 year ago

Natural treatments for hair loss, specifically peppermint oil and rosemary oil; how they can be used as a supplementary or alternative treatment to pharmaceuticals such as finasteride and minoxidil; and the personal experience of the user Divallo, who has seen an increase in density and thickness after using these oils for around 2.5 years. The post also touches on the potential antifungal properties of the oils and their effects on cutaneous blood flow.

community Second update: almost 3.5 months min microneedling 1.5mm once a week ketoconazole shampoo 4 times a week

in Update 590 upvotes 2 years ago

A user's hair loss treatment regimen, which includes minoxidil, ketoconazole shampoo and microneedling; some participants questioned the results due to previous posts about hair transplants, but others agreed that quick results are possible with certain treatments.

community HMI-115 update: Chime Biologics and Hope Medicine Enter Manufacturing Agreement to Speed up the Launch of First-in-class Antibody Drug HMI-115 Targeting Endometriosis and Androgenic Alopecia

in Research/Science 108 upvotes 1 year ago

Chime Biologics and Hope Medicine are speeding up the launch of a first-in-class antibody drug, HMI-115, for endometriosis and androgenic alopecia. The treatment involves a series of subcutaneous injections, has shown promising results in phase 1, and continues to promote hair regrowth even after the treatment is stopped.

community Why is everyone not directly advised Dutasteride?

in Finasteride/Dutasteride 165 upvotes 1 month ago

Dutasteride is less commonly prescribed for hair loss because it is not FDA-approved for this purpose, unlike finasteride, which is more accessible and preferred due to fewer side effects. Dutasteride may be more effective in reducing DHT but has a longer half-life and potentially more significant side effects.

Similar Research

5 / 1000+ results

research Cutaneous T-Cell Lymphoma Outcomes During COVID-19

September 2021 in “Journal of the American Academy of Dermatology”

CTCL patients can safely continue treatment during COVID-19 with proper safety measures.

Interferon in the Treatment of Cutaneous T-Cell Lymphoma

research Cutaneous T-Cell Lymphoma

11 citations, October 2001 in “Dermatologic Clinics”

The document concludes that DAB389-IL2 is promising for treating refractory cutaneous T-cell lymphoma, but more research is needed on its effectiveness and side effect management.